Semler Scientific stands at a strategic crossroads, poised for a fundamental transformation. The medical diagnostics firm is charting a course to become a hybrid entity through a merger with Bitcoin-focused investor Strive, Inc. This radical shift raises a critical question: can it reverse the significant share price declines witnessed in recent months?
Analyst Sentiment and Valuation Upside
Market analysts are predominantly optimistic about the stock’s trajectory, despite inherent volatility. The consensus rating sits at “Moderate Buy,” with some firms issuing “Strong Buy” recommendations. Research from established houses like Benchmark and Maxim Group points to price targets ranging from $60 to $95 per share. These valuations suggest substantial upside potential from current trading levels, reflecting the anticipated worth of both the combined Bitcoin holdings and the legacy medical operations.
The Core of the Strategy: The Strive Merger
Central to this transformation is the proposed merger with Strive. A shareholder vote is scheduled for January 13, 2026. If approved, each share of Semler Scientific would be converted into 21.05 shares of Strive. The resulting combined company would manage one of the world’s largest corporate Bitcoin treasuries, holding over 10,900 BTC. To sharpen the focus on digital assets, Semler’s existing healthcare activities are to be restructured or potentially divested. The board of directors has issued a strong recommendation in favor of the transaction.
Should investors sell immediately? Or is it worth buying Semler Scientific?
Bitcoin as the Central Asset
Bitcoin has already emerged as a primary value driver for Semler. The company’s current treasury holds 5,021 BTC. The merger is designed to amplify this strategy. Strive aggressively pursues further Bitcoin acquisition, most recently through a $200 million capital raise. Management emphasizes equity-based financing for this strategy, aiming to sidestep interest rate risk and boost the “Bitcoin per share” metric.
Cost-Cutting Ahead of Integration
Running parallel to the merger plans is a severe cost-reduction initiative. Semler is reducing its workforce by approximately 37% to streamline operations ahead of the integration. This move is projected to yield monthly salary cost savings of $0.7 million to $1.1 million starting in January 2026. However, one-time severance charges of about $1.2 million will impact the current fiscal year. The objective is to enter the 2026 merger year with a leaner operational model.
While products such as QuantaFlo continue to represent the ongoing business, the upcoming shareholder decision on January 13 will be pivotal. It will reveal whether investors endorse this dramatic pivot toward a digital asset-focused future. The weeks leading to the vote are likely to be decisive for the stock’s performance.
Ad
Semler Scientific Stock: Buy or Sell?! New Semler Scientific Analysis from December 23 delivers the answer:
The latest Semler Scientific figures speak for themselves: Urgent action needed for Semler Scientific investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from December 23.
Semler Scientific: Buy or sell? Read more here...









